The Biofilm Production by Various Candida Species Isolated from Different Clinical Samples

Download Article

Authors : Sadaf Tabassum


Pathogenic fungi in the genus Candida can cause both superficial and serious systemic disease, and are now recognized as major agents of hospital-acquired infection.

Candida infections involve the formation of biofilms on implanted devices such as indwelling catheters or prosthetic heart valves. Nosocomial infections due to candida are also becoming increasingly important. Early and prompt diagnosis, proper treatment and prevention of candidemia due to biofilms pose a major challenge for microbiologists and clinicians worldwide. Biofilm is an aggregate of microorganism in which cell adhere to each other on a surface. It has been reported that organism in biofilms are more resistant to antimicrobial agents than there planktonic (free) form. Formation of a biofilm begins with the attachment of free-floating microorganisms to a surface. These first adhere to the surface initially through weak, reversible adhesion via Vander Waal forces. If the colonies are not immediately separated from the surface, they can anchor themselves more permanently using cell adhesion structures such as pilli. There are five stages of biofilm development such as i) initial attachment ii) irreversible attachment iii) maturation I iv) maturation II v) dispersion.


1.      Douglas J.L. Candida Biofilms and their role in infection, Review Trends in Microbiology, Jan 2003, vol. 11, 30-36.

2.      Pfaller M.A. Nosocomial Candidiasis: emerging species, reservoirs and modes of transmission. Cl. Infect. Dis., Oxford Jour. 1996 (suppl. 2) 589-94.

3.      Chandra J. Kuhn al; Biofilm formation by fungal pathogen Candida albicans: development architecture and drug resistance. Jour. Bacteriol. 2001 183(18) 5385-94.

4.      Watnick P. Kotler R. Biofilm: city of microbes, Jour. Of Bacteriol. May 2000 182(10) 2675-79.

5.      Glasgow/ biofilm

6.      Berry V. Badyal D. sensitivity of clinical isolates of Candida species to antifungal drugs org. art. J.K. science 2006 8(4)214-20.

7.      Mary A.J. Falkler W. Fungal biofilm and drug resistance. Emerg. Infect. Dis. 2004 Jan. 10(1); 14-19.

8.      Kokare C. Chakraborty S. et al; Biofilm: importance and applications.rev Ind. Jour. of Biotech. 2008 8,159-68.

9.      Chander J. Textbook of medical mycology, Mehta publications Ed.3rd, chapter20, Candidiasis, 266-83.

10.  Topley and Wilson’S Microbiology and Microbial infection: Medical Mycology Hodder Arnold publication Ed. 10th

11.  Shin J. Kee S. et al; Biofilm production by isolates of Candida species recovered from non neutropenic patients: comparison of bloodstream isolates from other sources. Jour. Of Cl. Microbiol. apr. 2002 40(4) 1244-48.

12.  Paanusorn S. Fernandez V. et al; Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection. Jour. of mycoses.2013, 56(3) 264-72.

13.  Mohandas al; Distribution of Candida species in different clinical isolates and their virulence: Biofilm formation, proteinase and phospholipase production: a study on hospitalized patients in Southern India. Jour. Glob. Infect.Dis.20113 (1):4-8.

14.  Lal P. Agarwal al; Biofilm formation by Candida albicans isolated from intrauterine devices. Ind. Jour. of Microbiol. 2008 48:438-444.

15.  Hawser S. Douglas J. Biofilm formation by Candida species on the surface of catheter material in vitro. Jour. of Infection and Immunity 1994 62(3):915-921.

16.  Silva al; Biofilm formation ability by Non albicans Candida species biofilm club 2007 33-41.

17.  Gokce al; Acid proteinase, phospholipase and biofilm production of Candida species isolated from blood culture J. Mycopathologia 2007 164(6) 265-269.

18.  Meleck INC et al; investigation virulence factors of clinical Candida isolates in relation to atmospheric condition and genotype. Turk. J. Med.2012 Sci.(sup 2): 1476-1483

19.  JPG image;

20.  Tumbarello M. Posteraro B. et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. Jour. Of Cl. Microbiol. June 2007 45(6) 1843-1850.

21.  Seneviratne CJ, Jin L, Samaranayeke LP. Biofilm lifestyle of Candida: A mini review Oral Dis. 2008; 14: 582-590.

22.  Aparna MS, Yadav S. Biofilms: Microbes and Disease. The Braz. J. Infect. Dis.2008; 12: 526-530.

23.  RM Dominic, S Shenoy, S Baliga. Candida biofilms in medical devices: Evolving trends. Kath Univ Medical J. 2007; Vol. 5, No. 3, Issue 19, 431-436.

24.  Baillie GS, Douglas LJ. Candida biofilm and their susceptibility to antifungal agents. Methods Enzymol.1999; 310:644–56.

25.  Segal, E. and D. Elad. Candida species and Blastoschizomycescapitatus. In: Agillo, L. and R. J. Hay (Eds).1998; Microbiology and Microbial Infection. New York, Arnold, pp: 423-460

26.  Chakrabarti A, Singh K, Das S. Changing face of nosocomial candidaemia. Indian J Med Microbiol.1999; 17:160–6.

27.  Vinitha, M and Ballal, M. Biofilm as virulence marker in Candida isolated from blood, World J for Medical Sciences 2007;2:46-48.